Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Small Cell Lung Carcinoma 3Multiple Myeloma 2Wilms Tumor 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Carcinoma, Merkel Cell 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 8fludarabine phosphate 7tagraxofusp 6venetoclax 5fludarabine 5Whole-Body Irradiation 4Mycophenolic Acid 4Methotrexate 4Thiotepa 3Dexamethasone 3Cytarabine 3Cyclosporine 3Calcium Dobesilate 3merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Vincristine 2Tacrolimus 2Specimen Handling 2Rituximab 2Peripheral Blood Stem Cell Transplantation 2Cyclosporins 2Azacitidine 2relmapirazin 1prednylidene 1lorvotuzumab mertansine 1exifone 1deltacortene 1azathiopurine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Blastic Plasmacytoid Dendritic Cell Neoplasm × lorvotuzumab mertansine × Clear all
NCT02420873 2018-08-28

An Open-label Phase II Study of Lorvotuzumab Mertansine

M.D. Anderson Cancer Center

Phase 2 Completed
9 enrolled 7 charts
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡